Cerebral Insufficiency Caused by Diazoxide in a Premature Neonate with Congenital Hyperinsulinism

Abstract Diazoxide is a peripheral vasodilator that has been used for intravenous treatment of hypertensive emergencies. However, it is currently used mainly for hyperinsulinemic hypoglycemia in lower dose orally, and its major side effects are edema and pulmonary hypertension. Herein, we report the first association between periventricular leukomalacia (PVL) and intractable hypotension due to diazoxide. A Japanese female premature infant showed hypoglycemia concomitant with hyperinsulinemia. She was diagnosed with congenital hyperinsulinism, and oral diazoxide was started. Six days after starting diazoxide, she suddenly showed peripheral coldness, oliguria, and severe hypotension. The hypotension was refractory to general vasopressor therapies and persisted even after the discontinuation of diazoxide. Cranial echography showed periventricular echodensities followed by cystic PVL. Low-dose vasopressin effectively treated the hypotension. This single case reminds us the serious adverse events of diazoxide that have been forgotten, especially in premature neonates.

[1]  Diva D. De León,et al.  Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide , 2018, The Journal of clinical endocrinology and metabolism.

[2]  Mitsuyoshi Hara,et al.  Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey) , 2018, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[3]  M. Vavilala,et al.  Hypertension After Severe Traumatic Brain Injury: Friend or Foe? , 2017, Journal of neurosurgical anesthesiology.

[4]  Li Zhang,et al.  Association between perinatal hypoxic-ischemia and periventricular leukomalacia in preterm infants: A systematic review and meta-analysis , 2017, PloS one.

[5]  S. Ida,et al.  Clinical practice guidelines for congenital hyperinsulinism , 2017, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[6]  M. Kawai Late‐onset circulatory collapse of prematurity , 2017, Pediatrics international : official journal of the Japan Pediatric Society.

[7]  T. Heike,et al.  High Prevalence of Severe Circulatory Complications with Diazoxide in Premature Infants , 2014, Neonatology.

[8]  P. Biban,et al.  Vasopressin and terlipressin in neonates and children with refractory septic shock. , 2013, Current drug metabolism.

[9]  Bing-qing Sun,et al.  The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism , 2012, Journal of pediatric endocrinology & metabolism : JPEM.

[10]  P. Dayton,et al.  A comparison of the binding of drugs to adult and cord plasma , 1971, European Journal of Clinical Pharmacology.

[11]  S. Mizroch,et al.  Hypotension and bradycardia following diazoxide and hydralazine therapy. , 1977, Journal of the American Medical Association (JAMA).

[12]  M. Razzaque,et al.  Side effects of diazoxide. , 1976, JAMA.

[13]  J. Milstein Hypoglycemia in the neonate. , 1971, Postgraduate medicine.